|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
839.96 USD |
+14.30% | +14.68% | +8.80% | |
April 20, 2025 at 02:37 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Eli Lilly Plans US Production of Latest Weight-loss Pill |
02:37am |
MT |
|
Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch |
Apr. 18 |
DJ |
|
Japan’s Nikkei notches best week in 3 months on trade deal hopes |
Apr. 18 |
RE |
|
Eli Lilly Releases Obesity Drug Zepbound in Japan |
Apr. 17 |
MT |
|
Wall Street choppy as Eli Lilly jumps, UnitedHealth plummets |
Apr. 17 |
RE |
|
Dow, Nasdaq Fall For Third Straight Day as Markets Log Weekly Losses |
Apr. 17 |
MT |
|
Equity Markets Close Mixed as Trump Calls for Rate Cuts |
Apr. 17 |
MT |
|
US Equities Markets End Mixed Thursday Ahead of Good Friday Holiday |
Apr. 17 |
MT |
|
Sector Update: Health Care Stocks Decline Late Afternoon |
Apr. 17 |
MT |
|
Health Care Slides After UnitedHealth Earnings – Health Care Roundup |
Apr. 17 |
DJ |
|
Equity Markets Mixed as Trump Calls for Interest Rate Cuts |
Apr. 17 |
MT |
|
UnitedHealth Sell-Off Drags Dow Lower Intraday; Markets Weigh Trump’s Remarks |
Apr. 17 |
MT |
|
Wall Street pauses stock, dollar sell-off amid trade talks |
Apr. 17 |
RE |
|
Wall Street choppy as Eli Lilly jumps, UnitedHealth plummets |
Apr. 17 |
RE |
|
Wall Street choppy as Eli Lilly jumps, UnitedHealth plummets |
Apr. 17 |
RE |
|
Lilly weight-loss pill works as well as Ozempic, shares surge |
Apr. 17 |
RE |
|
Sector Update: Health Care Stocks Softer Thursday Afternoon |
Apr. 17 |
MT |
|
US Equity Indexes Mixed in Choppy Trading as UnitedHealth Drags Dow |
Apr. 17 |
MT |
|
Wall Street mixed in choppy trading; UnitedHealth plummets |
Apr. 17 |
RE |
|
Top Midday Stories: Google Found Liable on 3 of 4 Counts in Antitrust Case; UnitedHealth Shares Tumble on Revenue Miss, Guidance Cut |
Apr. 17 |
MT |
|
FTSE 100 outshines Europe after ECB lowers rates |
Apr. 17 |
AN |
|
Eli Lilly’s Oral Diabetes Drug Met Expectations in Phase 3 Study, Truist Says |
Apr. 17 |
MT |
|
Eli Lilly Investigational Obesity Pill Helps Control Glucose Levels, Reduce Weight; Shares Rally |
Apr. 17 |
MT |
|
S&P 500, Nasdaq advance after selloff; UnitedHealth plunges |
Apr. 17 |
RE |
|
Eli Lilly Shares Rise as Potential Diabetes Treatment Meets Primary, Secondary Endpoints |
Apr. 17 |
MT |
LLY: Dynamic Chart
Eli Lilly and Company is one of the world’s leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
– endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems;
– oncology (19.4%);
– immunology diseases (9.8%);
– neurology (3.3%): primarily drugs used in treating depression and schizophrenia;
– other (2%).
Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
More about the company
Buy
Last Close Price
839.96USD
Average target price
1,006.09USD
Spread / Average Target
+19.78%
Consensus
